- PA5-17245 - Invitrogen Antibodies CDCP1 antibody

Submitted references The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, Tagliabue E, Campiglio M, Bianchi F
BMC cancer 2018 May 23;18(1):586

Cub domain-containing protein 1 negatively regulates TGF-β signaling and myofibroblast differentiation.

Noskovičová N, Heinzelmann K, Burgstaller G, Behr J, Eickelberg O
American journal of physiology. Lung cellular and molecular physiology 2018 May 1;314(5):L695-L707

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.

Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M
Oncotarget 2016 Oct 25;7(43):69649-69665

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of CDCP1 in HT-29 cells using a CDCP1 polyclonal antibody (Product # PA5-17245) (green). DNA is labeled using a fluorescent blue dye.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 CDCP1 expression in human primary TNBCs ( A ) FFPE TNBC sections were immunostained with polyclonal anti-CDCP1 (Thermo Fisher Scientific), and membrane staining intensity was scored as positive or negative as described in Materials and Methods. Scale bar: 50 mum (insets 2x). ( B ) Frequency distribution of human specimens by percentage of CDCP1-positive cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Genetic alterations in CDCP1 in human primary TNBCs ( A ) Physical map of 3p21.31 region (spanning CDCP1 ), including genomic clones selected for FISH experiments covering the CDCP1 locus, their size in Kb, and the genes that they encompass. Maps are derived from University of California Santa Cruz Genome Browser ( http://genome.ucsc.edu/ ), with adaptations. ( B ) Representative images of dual-color FISH using CDCP1 /CEP3 probes on FFPE human primary TNBC specimens, showing tumor cells with: > 3 red signals for CEP3 and > 3 green signals for the CDCP1 locus (polysomy); < 3 signals for CEP3 and > 3 green signals for CDCP1 (amplification); < 3 signals for CEP3 and < 3 green signals for CDCP1 (disomy); and > 3 signals for CEP3 and < 3 green signals for the CDCP1 locus (deletion). ( C ) Correlation analysis between percentage of FISH-positive cells with percentage of IHC-positive cells ( n = 75; p < 0.0001; Pearson r = 0.6121; 95% confidence interval 0.4472 to 0.7367).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 IHC staining of PDGFRbeta and CDCP1 in TNBC. FFPE sections of TNBC specimens were analyzed by IHC for PDGFRbeta and CDCP1. a Representative image of a PDGFRbeta- and CDCP1-positive case, with plasma membrane staining, at 10X and 40X magnification; b Representative image of a PDGFRbeta- and CDCP1-negative case, at 10X and 40X magnification

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Genetic alterations of CDCP1 in TNBC. FFPE sections of TNBC specimens were analyzed by dual-color FISH using for CDCP1 genetic alteration CDCP1/CEP3 probes on a FFPE sections of TNBC specimens FISH. a Representative image of TNBC specimen positive for CDCP1 IHC staining, showing tumor cells with > 3 red signals for CEP3 and > 3 green signals for the CDCP1 locus (polysomy); b Representative image of TNBC specimen negative for CDCP1 IHC staining, showing tumor cells with > 3 signals for CEP3 and < 3 green signals for the CDCP1 locus (deletion)

PA5-17245

Antibody data